ARS Pharmaceuticals, Inc.
SPRY
$9.72
-$0.08-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 97.13% | -90.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 97.13% | -90.79% | |||
| Cost of Revenue | 122.91% | 3.96% | |||
| Gross Profit | 70.56% | -95.25% | |||
| SG&A Expenses | 32.13% | 15.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 40.27% | 14.64% | |||
| Operating Income | -28.07% | -178.77% | |||
| Income Before Tax | -32.24% | -167.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.24% | -167.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.24% | -167.97% | |||
| EBIT | -28.07% | -178.77% | |||
| EBITDA | -28.29% | -178.13% | |||
| EPS Basic | -31.84% | -167.51% | |||
| Normalized Basic EPS | -24.65% | -173.24% | |||
| EPS Diluted | -31.84% | -182.31% | |||
| Normalized Diluted EPS | -24.65% | -189.66% | |||
| Average Basic Shares Outstanding | 0.31% | 0.68% | |||
| Average Diluted Shares Outstanding | 0.31% | -17.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||